PDMR Shareholding/SIP and Total Voting Rights

Diaceutics PLC

06 October 2026

 

Diaceutics PLC

PDMR Shareholding/Share Incentive Plan and Total Voting Rights

New York, Belfast and London, 6 October 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, has been notified that on 30 September 2026, Global Shares Trustees (UK) Limited (the "UK Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares of £0.002 in the capital of the Company ("Shares") on behalf of Susanne Munksted, Jordan Clark and Nick Roberts (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for  employees. These purchases will be made each month until further notice.

In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.

As announced on 2 October 2023, application was made to AIM for a block listing of 1,500,000 Shares to facilitate the admission of the Shares to trading following the exercise of options inter alia under the SIP Schemes. The matched share awards for the UK PDMRs, along with those for all other participants in the UK SIP Scheme, have been settled by the Company issuing 3,839 Shares on 2 October 2026 to the UK Trust. The Trust will hold these Shares on behalf of participants until they vest in accordance with the UK Scheme rules.

During the period from the last Total Voting Rights Announcement on 2 September 2026, 76,053 Shares were allotted to settle certain employee share option exercises during July 2026 in addition to the Shares allotted as a result of the Share Incentive Plan transactions announced today. As a result, the number of Shares Diaceutics has in issue is 85,234,252. This figure may be used by shareholders in the Company as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Diaceutics PLC
Ryan Keeling, Chief Executive Officer	Tel: [phone]
Nick Roberts, Chief Financial Officer	[e-mail]
Canaccord Genuity Limited (Nomad & Broker)	Tel: [phone]
Simon Bridges, Andrew Potts, Harry Rees

About Diaceutics

At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Susanne Munksted
2	Reason for notification
a.	Position/Status	Chief Precision Medicine Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")
c.	Price(s) and volume(s)		Share purchase:
			Price(s)	Volume(s)
			192.0 p	77
			Conditional share award:
			Price(s)	Volume(s)
			Nil	77
e.	Date of the transaction	Share purchase and Conditional share award: 30 September 2026
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Jordan Clark
2	Reason for notification
a.	Position/Status	Chief Data Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")
c.	Price(s) and volume(s)		Share purchase:
			Price(s)	Volume(s)
			192.0 p	78
			Matched share award:
			Price(s)	Volume(s)
			Nil	78
e.	Date of the transaction	Share purchase and Matched Share award: 30 September 2026
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Matched Share Award: Off-Market

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Nick Roberts
2	Reason for notification
a.	Position/Status	Chief Finance Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")
c.	Price(s) and volume(s)		Share purchase:
			Price(s)	Volume(s)
			192.0 p	78
			Matched share award:
			Price(s)	Volume(s)
			Nil	78
e.	Date of the transaction	Share purchase and Matched Share award: 30 September 2026
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Matched Share Award: Off-Market

 

END